drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00514 | DB00599 | 506 | 682 | [
"DDInter527",
"DDInter1795"
] | Dextromethorphan | Thiopental | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Moderate | 1 | [
[
[
506,
24,
682
]
],
[
[
506,
63,
1023
],
[
1023,
1,
682
]
],
[
[
506,
6,
8374
],
[
8374,
45,
682
]
],
[
[
506,
63,
752
],
[
752,
2... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Thiopental (Compound)
Dextromethorphan may cause a moderate interactio... |
DB11978 | DB14723 | 124 | 159 | [
"DDInter822",
"DDInter1026"
] | Glasdegib | Larotrectinib | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
124,
24,
159
]
],
[
[
124,
63,
479
],
[
479,
23,
159
]
],
[
[
124,
64,
318
],
[
318,
23,
159
]
],
[
[
124,
23,
466
],
[
466,
23,... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Glasdegib may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause... |
DB09052 | DB14761 | 250 | 242 | [
"DDInter220",
"DDInter1578"
] | Blinatumomab | Remdesivir | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
250,
24,
242
]
],
[
[
250,
64,
1377
],
[
1377,
24,
242
]
],
[
[
250,
24,
384
],
[
384,
24,
242
]
],
[
[
250,
63,
482
],
[
482,
2... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflu... | Blinatumomab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may ... |
DB04896 | DB08816 | 901 | 578 | [
"DDInter1220",
"DDInter1802"
] | Milnacipran | Ticagrelor | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
901,
24,
578
]
],
[
[
901,
21,
28646
],
[
28646,
60,
578
]
],
[
[
901,
63,
1578
],
[
1578,
24,
578
]
],
[
[
901,
64,
1039
],
[
1039,
... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Milnacipran",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
... | Milnacipran (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin m... |
DB00675 | DB12015 | 888 | 1,033 | [
"DDInter1744",
"DDInter53"
] | Tamoxifen | Alpelisib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
888,
24,
1033
]
],
[
[
888,
23,
1135
],
[
1135,
23,
1033
]
],
[
[
888,
75,
576
],
[
576,
24,
1033
]
],
[
[
888,
24,
1144
],
[
1144,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"N... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Tamoxifen (Compound) resembles Methadone (Compound) and Tamoxifen may lead to a major life threatening interaction when ... |
DB04868 | DB09065 | 478 | 760 | [
"DDInter1293",
"DDInter424"
] | Nilotinib | Cobicistat | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
478,
25,
760
]
],
[
[
478,
62,
479
],
[
479,
23,
760
]
],
[
[
478,
24,
1627
],
[
1627,
23,
760
]
],
[
[
478,
23,
271
],
[
271,
2... | [
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol m... |
DB08870 | DB13007 | 850 | 1,060 | [
"DDInter228",
"DDInter642"
] | Brentuximab vedotin | Enfortumab vedotin | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
850,
24,
1060
]
],
[
[
850,
24,
129
],
[
129,
23,
1060
]
],
[
[
850,
63,
1593
],
[
1593,
24,
1060
]
],
[
[
850,
24,
270
],
[
270,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"E... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when take... |
DB01069 | DB11901 | 401 | 913 | [
"DDInter1533",
"DDInter107"
] | Promethazine | Apalutamide | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
401,
24,
913
]
],
[
[
401,
63,
312
],
[
312,
23,
913
]
],
[
[
401,
62,
112
],
[
112,
23,
913
]
],
[
[
401,
24,
271
],
[
271,
23,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Me... |
DB01206 | DB08870 | 37 | 850 | [
"DDInter1086",
"DDInter228"
] | Lomustine | Brentuximab vedotin | An alkylating agent of value against both hematologic malignancies and solid tumors. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
37,
24,
850
]
],
[
[
37,
24,
496
],
[
496,
63,
850
]
],
[
[
37,
63,
611
],
[
611,
24,
850
]
],
[
[
37,
24,
259
],
[
259,
24,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Lomustine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00278 | DB09068 | 291 | 1,427 | [
"DDInter117",
"DDInter1948"
] | Argatroban | Vortioxetine | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
291,
24,
1427
]
],
[
[
291,
64,
25
],
[
25,
24,
1427
]
],
[
[
291,
25,
256
],
[
256,
24,
1427
]
],
[
[
291,
24,
1061
],
[
1061,
... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistr... | Argatroban may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Argatroban may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate ... |
DB00562 | DB11093 | 1,014 | 636 | [
"DDInter188",
"DDInter273"
] | Benzthiazide | Calcium citrate | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Calcium citrate is a salt typically used as a source of calcium in a variety of over the counter supplements. | Moderate | 1 | [
[
[
1014,
24,
636
]
],
[
[
1014,
23,
1572
],
[
1572,
24,
636
]
],
[
[
1014,
40,
504
],
[
504,
24,
636
]
],
[
[
1014,
1,
811
],
[
811,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium citrate"
]
],
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
... | Benzthiazide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium citrate
Benzthiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause ... |
DB06589 | DB12130 | 1,250 | 1,017 | [
"DDInter1400",
"DDInter1094"
] | Pazopanib | Lorlatinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1250,
24,
1017
]
],
[
[
1250,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1250,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1250,
35,
786
],
[
786... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarote... |
DB06228 | DB06754 | 792 | 707 | [
"DDInter1609",
"DDInter471"
] | Rivaroxaban | Danaparoid | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
792,
25,
707
]
],
[
[
792,
23,
944
],
[
944,
62,
707
]
],
[
[
792,
24,
298
],
[
298,
63,
707
]
],
[
[
792,
63,
901
],
[
901,
24,... | [
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Rivaroxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C m... |
DB00041 | DB11988 | 1,648 | 270 | [
"DDInter38",
"DDInter1321"
] | Aldesleukin | Ocrelizumab | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1648,
24,
270
]
],
[
[
1648,
24,
134
],
[
134,
24,
270
]
],
[
[
1648,
24,
287
],
[
287,
63,
270
]
],
[
[
1648,
63,
1184
],
[
1184,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumara... |
DB00377 | DB00556 | 1,494 | 1,262 | [
"DDInter1382",
"DDInter1429"
] | Palonosetron | Perflutren | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Moderate | 1 | [
[
[
1494,
24,
1262
]
],
[
[
1494,
24,
679
],
[
679,
1,
1262
]
],
[
[
1494,
21,
29093
],
[
29093,
60,
1262
]
],
[
[
1494,
23,
112
],
[
112,... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
],
... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane and Sevoflurane (Compound) resembles Perflutren (Compound)
Palonosetron (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Perflutren (Compound)
Palonosetron may cause a minor interaction... |
DB00553 | DB01069 | 92 | 401 | [
"DDInter1177",
"DDInter1533"
] | Methoxsalen | Promethazine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
92,
24,
401
]
],
[
[
92,
24,
146
],
[
146,
24,
401
]
],
[
[
92,
24,
820
],
[
820,
63,
401
]
],
[
[
92,
21,
28787
],
[
28787,
60,... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
],
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine a... |
DB00675 | DB12245 | 888 | 823 | [
"DDInter1744",
"DDInter1863"
] | Tamoxifen | Triclabendazole | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
888,
24,
823
]
],
[
[
888,
23,
1247
],
[
1247,
23,
823
]
],
[
[
888,
24,
1612
],
[
1612,
24,
823
]
],
[
[
888,
63,
1010
],
[
1010,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavi... |
DB00395 | DB01105 | 210 | 222 | [
"DDInter301",
"DDInter1665"
] | Carisoprodol | Sibutramine | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
210,
24,
222
]
],
[
[
210,
21,
28852
],
[
28852,
60,
222
]
],
[
[
210,
24,
1297
],
[
1297,
62,
222
]
],
[
[
210,
24,
128
],
[
128,
... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Carisoprodol",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) ... | Carisoprodol (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Sibutramine (Compound)
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a minor interaction that can limit clinical effects when taken wit... |
DB00374 | DB01294 | 1,061 | 266 | [
"DDInter1852",
"DDInter215"
] | Treprostinil | Bismuth subsalicylate | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1061,
24,
266
]
],
[
[
1061,
7,
7720
],
[
7720,
45,
266
]
],
[
[
1061,
21,
28643
],
[
28643,
60,
266
]
],
[
[
1061,
24,
1347
],
[
1347... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Treprostinil",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound ... | Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Bismuth subsalicylate (Compound)
Treprostinil (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases whe... |
DB01234 | DB08815 | 1,220 | 154 | [
"DDInter513",
"DDInter1104"
] | Dexamethasone | Lurasidone | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1220,
24,
154
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1220,
21,
28963
],
[
28963,
60,
154
]
],
[
[
1220,
24,
1033
],
[
1033... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Dexamethasone (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Lurasidone (Compound)
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and ... |
DB08875 | DB08901 | 1,618 | 1,468 | [
"DDInter262",
"DDInter1492"
] | Cabozantinib | Ponatinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1618,
25,
1468
]
],
[
[
1618,
64,
478
],
[
478,
24,
1468
]
],
[
[
1618,
63,
307
],
[
307,
23,
1468
]
],
[
[
1618,
24,
286
],
[
286,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} ... | Cabozantinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a... |
DB00662 | DB01242 | 717 | 1,237 | [
"DDInter1873",
"DDInter410"
] | Trimethobenzamide | Clomipramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
717,
24,
1237
]
],
[
[
717,
24,
684
],
[
684,
1,
1237
]
],
[
[
717,
63,
902
],
[
902,
40,
1237
]
],
[
[
717,
24,
272
],
[
272,
2... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazin... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomip... |
DB00264 | DB01064 | 88 | 1,148 | [
"DDInter1200",
"DDInter987"
] | Metoprolol | Isoprenaline | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
88,
24,
1148
]
],
[
[
88,
24,
1636
],
[
1636,
24,
1148
]
],
[
[
88,
40,
887
],
[
887,
24,
1148
]
],
[
[
88,
6,
1704
],
[
1704,
4... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that c... |
DB00467 | DB01229 | 1,467 | 973 | [
"DDInter644",
"DDInter1377"
] | Enoxacin | Paclitaxel | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Minor | 0 | [
[
[
1467,
23,
973
]
],
[
[
1467,
18,
4930
],
[
4930,
57,
973
]
],
[
[
1467,
6,
3199
],
[
3199,
57,
973
]
],
[
[
1467,
1,
872
],
[
872,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Enoxacin",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Compoun... | Enoxacin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Paclitaxel (Compound)
Enoxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Paclitaxel (Compound)
Enoxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clin... |
DB00787 | DB14509 | 387 | 1,399 | [
"DDInter25",
"DDInter1081"
] | Acyclovir | Lithium carbonate | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
387,
24,
1399
]
],
[
[
387,
62,
1031
],
[
1031,
24,
1399
]
],
[
[
387,
63,
372
],
[
372,
24,
1399
]
],
[
[
387,
24,
1532
],
[
1532,
... | [
[
[
"Acyclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acyclovir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
... | Acyclovir may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Acyclovir may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine an... |
DB00673 | DB00912 | 723 | 473 | [
"DDInter112",
"DDInter1581"
] | Aprepitant | Repaglinide | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
723,
24,
473
]
],
[
[
723,
6,
8374
],
[
8374,
45,
473
]
],
[
[
723,
21,
28763
],
[
28763,
60,
473
]
],
[
[
723,
63,
798
],
[
798,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound)
Aprepitant (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Repaglinide (Compound)
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and ... |
DB01045 | DB06176 | 463 | 1,342 | [
"DDInter1590",
"DDInter1616"
] | Rifampicin | Romidepsin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
463,
25,
1342
]
],
[
[
463,
63,
112
],
[
112,
23,
1342
]
],
[
[
463,
25,
1491
],
[
1491,
63,
1342
]
],
[
[
463,
24,
1619
],
[
1619,
... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Rifampicin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may ... |
DB00726 | DB00835 | 1,164 | 100 | [
"DDInter1876",
"DDInter245"
] | Trimipramine | Brompheniramine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1164,
24,
100
]
],
[
[
1164,
24,
832
],
[
832,
24,
100
]
],
[
[
1164,
1,
508
],
[
508,
24,
100
]
],
[
[
1164,
63,
128
],
[
128,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trimipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interac... |
DB00637 | DB01069 | 1,557 | 401 | [
"DDInter128",
"DDInter1533"
] | Astemizole | Promethazine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1557,
24,
401
]
],
[
[
1557,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1557,
24,
1335
],
[
1335,
24,
401
]
],
[
[
1557,
6,
12523
],
[
12523... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarba... |
DB01024 | DB01432 | 1,096 | 857 | [
"DDInter1252",
"DDInter368"
] | Mycophenolic acid | Cholestyramine | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Major | 2 | [
[
[
1096,
25,
857
]
],
[
[
1096,
63,
1620
],
[
1620,
23,
857
]
],
[
[
1096,
63,
91
],
[
91,
24,
857
]
],
[
[
1096,
25,
1377
],
[
1377,
... | [
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cholestyramine"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with V... |
DB08881 | DB09083 | 868 | 880 | [
"DDInter1925",
"DDInter996"
] | Vemurafenib | Ivabradine | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
868,
25,
880
]
],
[
[
868,
63,
480
],
[
480,
24,
880
]
],
[
[
868,
24,
159
],
[
159,
63,
880
]
],
[
[
868,
24,
1040
],
[
1040,
2... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoter... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB00758 | DB06081 | 1,347 | 1,046 | [
"DDInter413",
"DDInter286"
] | Clopidogrel | Caplacizumab | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
1347,
25,
1046
]
],
[
[
1347,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
1347,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1347,
24,
1412
],
[
14... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfe... |
DB00604 | DB01238 | 1,425 | 673 | [
"DDInter385",
"DDInter118"
] | Cisapride | Aripiprazole | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1425,
24,
673
]
],
[
[
1425,
25,
851
],
[
851,
1,
673
]
],
[
[
1425,
25,
827
],
[
827,
40,
673
]
],
[
[
1425,
6,
3958
],
[
3958,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
"Nefazodone... | Cisapride may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Cisapride may lead to a major life threatening interaction when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Cisapride (Compound) binds KCN... |
DB01015 | DB01128 | 1,247 | 918 | [
"DDInter1724",
"DDInter204"
] | Sulfamethoxazole | Bicalutamide | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Minor | 0 | [
[
[
1247,
23,
918
]
],
[
[
1247,
23,
129
],
[
129,
40,
918
]
],
[
[
1247,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1247,
21,
29106
],
[
29106,
... | [
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bicalutamide"
]
],
[
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
... | Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Sulfamethoxazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Sulfamethoxazole (Compound) causes Myalgia (Side... |
DB00213 | DB11613 | 837 | 1,519 | [
"DDInter1388",
"DDInter1924"
] | Pantoprazole | Velpatasvir | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Major | 2 | [
[
[
837,
25,
1519
]
],
[
[
837,
24,
594
],
[
594,
24,
1519
]
],
[
[
837,
1,
379
],
[
379,
25,
1519
]
],
[
[
837,
24,
129
],
[
129,
2... | [
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosuti... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening i... |
DB00397 | DB00850 | 1,466 | 1,630 | [
"DDInter1458",
"DDInter1432"
] | Phenylpropanolamine | Perphenazine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
1466,
24,
1630
]
],
[
[
1466,
24,
1178
],
[
1178,
40,
1630
]
],
[
[
1466,
6,
4886
],
[
4886,
45,
1630
]
],
[
[
1466,
7,
4634
],
[
4634... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluo... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Perphenazine (Compound)
Phenylpropanolamine (Compound) binds DRD1 (Gene) and DRD1 (Gene) is bound by Perphenazine (Compound)
Phenylpropanolamine (Compound) upregul... |
DB00585 | DB01263 | 1,127 | 859 | [
"DDInter1309",
"DDInter1494"
] | Nizatidine | Posaconazole | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1127,
24,
859
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1127,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1127,
23,
286
],
[
286,
... | [
[
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Nizatidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Nizatidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide a... |
DB00398 | DB08886 | 79 | 637 | [
"DDInter1702",
"DDInter126"
] | Sorafenib | Asparaginase Erwinia chrysanthemi | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
79,
24,
637
]
],
[
[
79,
24,
392
],
[
392,
24,
637
]
],
[
[
79,
24,
1421
],
[
1421,
63,
637
]
],
[
[
79,
63,
482
],
[
482,
24,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapati... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Be... |
DB00758 | DB01225 | 1,347 | 500 | [
"DDInter413",
"DDInter645"
] | Clopidogrel | Enoxaparin | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
1347,
25,
500
]
],
[
[
1347,
21,
29173
],
[
29173,
60,
500
]
],
[
[
1347,
23,
1631
],
[
1631,
62,
500
]
],
[
[
1347,
24,
1004
],
[
100... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Clopidogrel",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema peripheral"
],
[
"Oedema peripheral",
"{u} (Side Effect) is c... | Clopidogrel (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Enoxaparin (Compound)
Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken wi... |
DB00022 | DB08871 | 268 | 36 | [
"DDInter1408",
"DDInter666"
] | Peginterferon alfa-2b | Eribulin | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
268,
24,
36
]
],
[
[
268,
24,
563
],
[
563,
24,
36
]
],
[
[
268,
24,
713
],
[
713,
63,
36
]
],
[
[
268,
63,
1451
],
[
1451,
24,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gancicl... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with... |
DB01211 | DB08893 | 609 | 271 | [
"DDInter393",
"DDInter1229"
] | Clarithromycin | Mirabegron | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Minor | 0 | [
[
[
609,
23,
271
]
],
[
[
609,
63,
371
],
[
371,
40,
271
]
],
[
[
609,
6,
4973
],
[
4973,
45,
271
]
],
[
[
609,
21,
28956
],
[
28956,
... | [
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Mirabegron (Compound)
Clarithromycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)
Clarithromycin (Compound) causes Palpitations (Side Effect... |
DB00556 | DB06176 | 1,262 | 1,342 | [
"DDInter1429",
"DDInter1616"
] | Perflutren | Romidepsin | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1262,
24,
1342
]
],
[
[
1262,
23,
112
],
[
112,
23,
1342
]
],
[
[
1262,
24,
485
],
[
485,
24,
1342
]
],
[
[
1262,
24,
1616
],
[
1616,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pen... |
DB00570 | DB01206 | 147 | 37 | [
"DDInter1936",
"DDInter1086"
] | Vinblastine | Lomustine | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | An alkylating agent of value against both hematologic malignancies and solid tumors. | Minor | 0 | [
[
[
147,
23,
37
]
],
[
[
147,
5,
11555
],
[
11555,
44,
37
]
],
[
[
147,
6,
8374
],
[
8374,
45,
37
]
],
[
[
147,
21,
28722
],
[
28722,
... | [
[
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomustine"
]
],
[
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease... | Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Vinblastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound)
Vinblastine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine ... |
DB00414 | DB09381 | 590 | 192 | [
"DDInter16",
"DDInter678"
] | Acetohexamide | Esterified estrogens | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone. Preparations contain 75% to 85% sodium estrone sulfate and 6% to 15% sodium equilin sulfate such that the total is not <90%. Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of me... | Moderate | 1 | [
[
[
590,
24,
192
]
],
[
[
590,
24,
752
],
[
752,
23,
192
]
],
[
[
590,
24,
1019
],
[
1019,
63,
192
]
],
[
[
590,
24,
5
],
[
5,
24,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Esterified estrogens
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Deflaza... |
DB00424 | DB00557 | 19 | 252 | [
"DDInter896",
"DDInter895"
] | Hyoscyamine | Hydroxyzine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
19,
24,
252
]
],
[
[
19,
24,
1630
],
[
1630,
1,
252
]
],
[
[
19,
24,
623
],
[
623,
40,
252
]
],
[
[
19,
24,
537
],
[
537,
63,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Co... |
DB00341 | DB04908 | 1,242 | 1,671 | [
"DDInter343",
"DDInter741"
] | Cetirizine | Flibanserin | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed lack of efficacy in trials and was further developed as a hypoactive sexual disorder... | Moderate | 1 | [
[
[
1242,
24,
1671
]
],
[
[
1242,
24,
830
],
[
830,
24,
1671
]
],
[
[
1242,
40,
1413
],
[
1413,
24,
1671
]
],
[
[
1242,
24,
407
],
[
407,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flibanserin"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Flibanserin
Cetirizine (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction t... |
DB00683 | DB06589 | 1,382 | 1,250 | [
"DDInter1212",
"DDInter1400"
] | Midazolam | Pazopanib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1382,
24,
1250
]
],
[
[
1382,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
1382,
18,
10773
],
[
10773,
57,
1250
]
],
[
[
1382,
21,
29264
],
[
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Midazolam (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is downregulated by Pazopanib (Compound)
Midazolam (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Mi... |
DB08870 | DB11828 | 850 | 1,406 | [
"DDInter228",
"DDInter1281"
] | Brentuximab vedotin | Neratinib | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
850,
24,
1406
]
],
[
[
850,
63,
392
],
[
392,
24,
1406
]
],
[
[
850,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
850,
24,
710
],
[
710,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide and Ter... |
DB00776 | DB04868 | 1,335 | 478 | [
"DDInter1360",
"DDInter1293"
] | Oxcarbazepine | Nilotinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1335,
24,
478
]
],
[
[
1335,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1335,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1335,
7,
8587
],
[
8587,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Oxcarbazepine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Oxcarbazepine (C... |
DB00679 | DB00857 | 684 | 1,387 | [
"DDInter1796",
"DDInter1768"
] | Thioridazine | Terbinafine | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epox... | Major | 2 | [
[
[
684,
25,
1387
]
],
[
[
684,
6,
3486
],
[
3486,
45,
1387
]
],
[
[
684,
7,
6134
],
[
6134,
45,
1387
]
],
[
[
684,
7,
4634
],
[
4634,
... | [
[
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terbinafine"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Te... | Thioridazine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Terbinafine (Compound)
Thioridazine (Compound) upregulates SQLE (Gene) and SQLE (Gene) is bound by Terbinafine (Compound)
Thioridazine (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Terbinafine (Compound)
Thioridazine (Com... |
DB00572 | DB04843 | 85 | 1,511 | [
"DDInter136",
"DDInter1149"
] | Atropine | Mepenzolate | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
85,
24,
1511
]
],
[
[
85,
24,
675
],
[
675,
24,
1511
]
],
[
[
85,
63,
194
],
[
194,
24,
1511
]
],
[
[
85,
24,
1429
],
[
1429,
63... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Darifena... |
DB00470 | DB01589 | 530 | 481 | [
"DDInter601",
"DDInter1552"
] | Dronabinol | Quazepam | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
530,
24,
481
]
],
[
[
530,
24,
1216
],
[
1216,
1,
481
]
],
[
[
530,
63,
523
],
[
523,
1,
481
]
],
[
[
530,
63,
905
],
[
905,
40,... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam (Compound)
Dron... |
DB00384 | DB06779 | 1,275 | 365 | [
"DDInter1859",
"DDInter470"
] | Triamterene | Dalteparin | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it a... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
1275,
24,
365
]
],
[
[
1275,
24,
222
],
[
222,
24,
365
]
],
[
[
1275,
24,
1274
],
[
1274,
25,
365
]
],
[
[
1275,
24,
802
],
[
802,
... | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and ... |
DB00601 | DB08904 | 453 | 375 | [
"DDInter1073",
"DDInter342"
] | Linezolid | Certolizumab pegol | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
453,
25,
375
]
],
[
[
453,
24,
1047
],
[
1047,
24,
375
]
],
[
[
453,
24,
1434
],
[
1434,
63,
375
]
],
[
[
453,
63,
66
],
[
66,
2... | [
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Linezolid may cause a moderate interaction that could exacerbate diseases when take... |
DB09104 | DB11921 | 286 | 1,019 | [
"DDInter1118",
"DDInter492"
] | Magnesium hydroxide | Deflazacort | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
286,
24,
1019
]
],
[
[
286,
63,
443
],
[
443,
24,
1019
]
],
[
[
286,
62,
1603
],
[
1603,
24,
1019
]
],
[
[
286,
24,
1375
],
[
1375,
... | [
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironol... | Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Magnesium hydroxide may cause a minor interaction that can limit clinical effects when taken w... |
DB00280 | DB11834 | 494 | 1,303 | [
"DDInter575",
"DDInter849"
] | Disopyramide | Guselkumab | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
494,
24,
1303
]
],
[
[
494,
63,
58
],
[
58,
24,
1303
]
],
[
[
494,
24,
608
],
[
608,
24,
1303
]
],
[
[
494,
23,
126
],
[
126,
24... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidoc... |
DB00342 | DB09082 | 1,181 | 659 | [
"DDInter1770",
"DDInter1934"
] | Terfenadine | Vilanterol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1181,
24,
659
]
],
[
[
1181,
63,
1570
],
[
1570,
24,
659
]
],
[
[
1181,
24,
927
],
[
927,
63,
659
]
],
[
[
1181,
25,
1069
],
[
1069,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and... |
DB00208 | DB00532 | 1,018 | 208 | [
"DDInter1804",
"DDInter1152"
] | Ticlopidine | Mephenytoin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
1018,
24,
208
]
],
[
[
1018,
25,
4
],
[
4,
63,
208
]
],
[
[
1018,
23,
891
],
[
891,
63,
208
]
],
[
[
1018,
63,
1560
],
[
1560,
2... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[... | Ticlopidine may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Predn... |
DB00640 | DB00738 | 1,585 | 485 | [
"DDInter31",
"DDInter1420"
] | Adenosine | Pentamidine | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
1585,
24,
485
]
],
[
[
1585,
18,
10699
],
[
10699,
57,
485
]
],
[
[
1585,
21,
28817
],
[
28817,
60,
485
]
],
[
[
1585,
24,
971
],
[
97... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {... | Adenosine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Pentamidine (Compound)
Adenosine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Pentamidine (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00431 | DB00652 | 1,503 | 234 | [
"DDInter1072",
"DDInter1421"
] | Lindane | Pentazocine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
1503,
24,
234
]
],
[
[
1503,
24,
1359
],
[
1359,
40,
234
]
],
[
[
1503,
21,
28762
],
[
28762,
60,
234
]
],
[
[
1503,
24,
1264
],
[
126... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[
"De... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Lindane (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Pentazocine (Compound)
Lindane may cause a moderate interaction that could ex... |
DB09293 | DB11921 | 116 | 1,019 | [
"DDInter954",
"DDInter492"
] | Iodide I-131 | Deflazacort | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
116,
24,
1019
]
],
[
[
116,
63,
914
],
[
914,
24,
1019
]
],
[
[
116,
24,
877
],
[
877,
63,
1019
]
],
[
[
116,
24,
1004
],
[
1004,
... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and ... |
DB00818 | DB06209 | 898 | 256 | [
"DDInter1538",
"DDInter1508"
] | Propofol | Prasugrel | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
898,
23,
256
]
],
[
[
898,
6,
10215
],
[
10215,
45,
256
]
],
[
[
898,
21,
29276
],
[
29276,
60,
256
]
],
[
[
898,
63,
888
],
[
888,
... | [
[
[
"Propofol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Propofol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Propofol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Prasugrel (Compound)
Propofol (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Prasugrel (Compound)
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxif... |
DB00029 | DB01175 | 25 | 318 | [
"DDInter99",
"DDInter672"
] | Anistreplase | Escitalopram | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
25,
24,
318
]
],
[
[
25,
24,
1230
],
[
1230,
1,
318
]
],
[
[
25,
25,
834
],
[
834,
24,
318
]
],
[
[
25,
24,
714
],
[
714,
24,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Anistreplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that co... |
DB01023 | DB06605 | 409 | 1,409 | [
"DDInter716",
"DDInter108"
] | Felodipine | Apixaban | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
409,
24,
1409
]
],
[
[
409,
6,
3486
],
[
3486,
45,
1409
]
],
[
[
409,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
409,
24,
1593
],
[
1593,... | [
[
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Felodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Felodipine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Apixaban (Compound)
Felodipine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizot... |
DB00361 | DB01005 | 134 | 995 | [
"DDInter1939",
"DDInter894"
] | Vinorelbine | Hydroxyurea | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
134,
24,
995
]
],
[
[
134,
5,
11555
],
[
11555,
44,
995
]
],
[
[
134,
6,
12523
],
[
12523,
45,
995
]
],
[
[
134,
18,
6896
],
[
6896,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Vinorelbine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dis... | Vinorelbine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Hydroxyurea (Compound)
Vinorelbine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxyurea (Compound)
Vinorelbine (Compound) downregulates RRM2 (Gene) and RRM2 (Gene) is bound by Hydroxyurea (Compo... |
DB00673 | DB00675 | 723 | 888 | [
"DDInter112",
"DDInter1744"
] | Aprepitant | Tamoxifen | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
723,
24,
888
]
],
[
[
723,
24,
939
],
[
939,
40,
888
]
],
[
[
723,
10,
11579
],
[
11579,
44,
888
]
],
[
[
723,
6,
6799
],
[
6799,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
[
... | Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Tamoxifen (Compound)
Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Tamoxifen (Compound)
Aprepitant (Compound) binds CYP3A7 (... |
DB00067 | DB06616 | 317 | 594 | [
"DDInter1921",
"DDInter224"
] | Vasopressin | Bosutinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
317,
24,
594
]
],
[
[
317,
23,
112
],
[
112,
23,
594
]
],
[
[
317,
24,
1559
],
[
1559,
24,
594
]
],
[
[
317,
24,
774
],
[
774,
6... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Fam... |
DB00153 | DB00524 | 1,331 | 811 | [
"DDInter662",
"DDInter1199"
] | Ergocalciferol | Metolazone | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Moderate | 1 | [
[
[
1331,
24,
811
]
],
[
[
1331,
24,
1605
],
[
1605,
40,
811
]
],
[
[
1331,
24,
1014
],
[
1014,
1,
811
]
],
[
[
1331,
21,
29000
],
[
29000... | [
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]
],
[
[
"Ergocalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
],
... | Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Indapamide and Indapamide (Compound) resembles Metolazone (Compound)
Ergocalciferol may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Metolazone... |
DB00176 | DB01254 | 529 | 1,213 | [
"DDInter770",
"DDInter484"
] | Fluvoxamine | Dasatinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
529,
24,
1213
]
],
[
[
529,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
529,
7,
3466
],
[
3466,
46,
1213
]
],
[
[
529,
18,
2551
],
[
2551,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Fluvoxamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Fluvoxamine (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Dasatinib (Compound)
Fluvoxamine (Compound) downregulates PFN1 (Gene) and PFN1 (Gene) is downregulated by Dasatinib (Compound)
Fluvoxamine (Compo... |
DB01222 | DB10429 | 617 | 200 | [
"DDInter246",
"DDInter282"
] | Budesonide | Candida albicans | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
617,
24,
200
]
],
[
[
617,
24,
1683
],
[
1683,
24,
200
]
],
[
[
617,
25,
976
],
[
976,
24,
200
]
],
[
[
617,
40,
1486
],
[
1486,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Budesonide may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ... |
DB00704 | DB08886 | 267 | 637 | [
"DDInter1263",
"DDInter126"
] | Naltrexone | Asparaginase Erwinia chrysanthemi | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
267,
24,
637
]
],
[
[
267,
63,
640
],
[
640,
24,
637
]
],
[
[
267,
24,
392
],
[
392,
24,
637
]
],
[
[
267,
24,
250
],
[
250,
63,... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acit... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00019 | DB00888 | 1,257 | 1,001 | [
"DDInter1405",
"DDInter1133"
] | Pegfilgrastim | Mechlorethamine | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Moderate | 1 | [
[
[
1257,
24,
1001
]
],
[
[
1257,
24,
450
],
[
450,
1,
1001
]
],
[
[
1257,
24,
51
],
[
51,
24,
1001
]
],
[
[
1257,
24,
738
],
[
738,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a mode... |
DB00169 | DB00794 | 386 | 759 | [
"DDInter367",
"DDInter1521"
] | Cholecalciferol | Primidone | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
386,
24,
759
]
],
[
[
386,
24,
697
],
[
697,
40,
759
]
],
[
[
386,
24,
362
],
[
362,
1,
759
]
],
[
[
386,
6,
6017
],
[
6017,
45,... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone... |
DB00889 | DB11113 | 1,133 | 657 | [
"DDInter840",
"DDInter307"
] | Granisetron | Castor oil | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1133,
24,
657
]
],
[
[
1133,
24,
1079
],
[
1079,
24,
657
]
],
[
[
1133,
24,
927
],
[
927,
63,
657
]
],
[
[
1133,
25,
540
],
[
540,
... | [
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Enc... |
DB00069 | DB08889 | 367 | 350 | [
"DDInter946",
"DDInter299"
] | Interferon alfacon-1 | Carfilzomib | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
367,
24,
350
]
],
[
[
367,
24,
1060
],
[
1060,
63,
350
]
],
[
[
367,
24,
482
],
[
482,
24,
350
]
],
[
[
367,
63,
1253
],
[
1253,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfort... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases ... |
DB00004 | DB00365 | 669 | 839 | [
"DDInter499",
"DDInter842"
] | Denileukin diftitox | Grepafloxacin | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Minor | 0 | [
[
[
669,
23,
839
]
],
[
[
669,
24,
1362
],
[
1362,
63,
839
]
],
[
[
669,
25,
770
],
[
770,
63,
839
]
],
[
[
669,
25,
1011
],
[
1011,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib... | Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin
Denileukin diftitox may lead to a major life threatening interaction when taken with Thalidomide and Tha... |
DB00662 | DB01075 | 717 | 1,376 | [
"DDInter1873",
"DDInter569"
] | Trimethobenzamide | Diphenhydramine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
717,
24,
1376
]
],
[
[
717,
24,
649
],
[
649,
63,
1376
]
],
[
[
717,
63,
128
],
[
128,
24,
1376
]
],
[
[
717,
24,
832
],
[
832,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedan... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with De... |
DB08871 | DB09020 | 36 | 28 | [
"DDInter666",
"DDInter212"
] | Eribulin | Bisacodyl | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
36,
24,
28
]
],
[
[
36,
63,
739
],
[
739,
24,
28
]
],
[
[
36,
64,
540
],
[
540,
24,
28
]
],
[
[
36,
24,
938
],
[
938,
63,
... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
... | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl
Eribulin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause... |
DB11652 | DB11793 | 1,155 | 738 | [
"DDInter1891",
"DDInter1297"
] | Tucatinib | Niraparib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1155,
24,
738
]
],
[
[
1155,
24,
466
],
[
466,
63,
738
]
],
[
[
1155,
64,
1213
],
[
1213,
24,
738
]
],
[
[
1155,
63,
663
],
[
663,
... | [
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tucatinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a... |
DB01166 | DB08918 | 477 | 41 | [
"DDInter379",
"DDInter1059"
] | Cilostazol | Levomilnacipran | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
477,
24,
41
]
],
[
[
477,
24,
901
],
[
901,
40,
41
]
],
[
[
477,
6,
10215
],
[
10215,
45,
41
]
],
[
[
477,
18,
5901
],
[
5901,
5... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Cilostazol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Levomilnacipran (Compound)
Cilostazol (Compound) downregulates GJA1 (Gene) and ... |
DB00563 | DB01603 | 663 | 1,366 | [
"DDInter1174",
"DDInter1195"
] | Methotrexate | Meticillin | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection. | Major | 2 | [
[
[
663,
25,
1366
]
],
[
[
663,
64,
790
],
[
790,
40,
1366
]
],
[
[
663,
25,
950
],
[
950,
40,
1366
]
],
[
[
663,
25,
339
],
[
339,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meticillin"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Piperacillin"
],
[
"Piperacillin",
... | Methotrexate may lead to a major life threatening interaction when taken with Piperacillin and Piperacillin (Compound) resembles Meticillin (Compound)
Methotrexate may lead to a major life threatening interaction when taken with Cloxacillin and Cloxacillin (Compound) resembles Meticillin (Compound)
Methotrexate may lea... |
DB00242 | DB00635 | 1,064 | 1,573 | [
"DDInter392",
"DDInter1515"
] | Cladribine | Prednisone | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Major | 2 | [
[
[
1064,
25,
1573
]
],
[
[
1064,
25,
175
],
[
175,
40,
1573
]
],
[
[
1064,
64,
1351
],
[
1351,
40,
1573
]
],
[
[
1064,
25,
251
],
[
251,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Cladribine may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Cladribine may lead to a major life threatening interaction when taken with Flunisolide and Flunisolide (Compound) resembles Prednisone (Compound)
Cladribine may lead to... |
DB00001 | DB06605 | 1,578 | 1,409 | [
"DDInter1037",
"DDInter108"
] | Lepirudin | Apixaban | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1578,
25,
1409
]
],
[
[
1578,
23,
539
],
[
539,
62,
1409
]
],
[
[
1578,
24,
109
],
[
109,
24,
1409
]
],
[
[
1578,
24,
41
],
[
41,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Lepirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"... | Lepirudin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cau... |
DB00039 | DB14962 | 1,253 | 1,363 | [
"DDInter1380",
"DDInter1847"
] | Palifermin | Trastuzumab deruxtecan | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Moderate | 1 | [
[
[
1253,
24,
1363
]
],
[
[
1253,
24,
599
],
[
599,
24,
1363
]
],
[
[
1253,
24,
1064
],
[
1064,
25,
1363
]
],
[
[
1253,
24,
599
],
[
599,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Cladrib... |
DB01132 | DB06817 | 1,130 | 809 | [
"DDInter1472",
"DDInter1563"
] | Pioglitazone | Raltegravir | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
1130,
23,
809
]
],
[
[
1130,
21,
29122
],
[
29122,
60,
809
]
],
[
[
1130,
24,
478
],
[
478,
23,
809
]
],
[
[
1130,
63,
1324
],
[
1324,... | [
[
[
"Pioglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Pioglitazone",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"... | Pioglitazone (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Raltegravir (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a minor interaction that can limit clinical effects ... |
DB00694 | DB01254 | 51 | 1,213 | [
"DDInter485",
"DDInter484"
] | Daunorubicin | Dasatinib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
51,
24,
1213
]
],
[
[
51,
5,
11555
],
[
11555,
44,
1213
]
],
[
[
51,
6,
17404
],
[
17404,
45,
1213
]
],
[
[
51,
18,
2030
],
[
2030,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Daunorubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dis... | Daunorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dasatinib (Compound)
Daunorubicin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Daunorubicin (Compound) downregulates ABL1 (Gene) and ABL1 (Gene) is bound by Dasatinib (Compound)
... |
DB01255 | DB06706 | 633 | 468 | [
"DDInter1078",
"DDInter985"
] | Lisdexamfetamine | Isometheptene | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
633,
24,
468
]
],
[
[
633,
6,
6771
],
[
6771,
45,
468
]
],
[
[
633,
63,
480
],
[
480,
24,
468
]
],
[
[
633,
24,
144
],
[
144,
63... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) binds {v} (Gene)",
"SLC18A2"
],
[
"SLC18A2",
"{u} (Gene) is bound by... | Lisdexamfetamine (Compound) binds SLC18A2 (Gene) and SLC18A2 (Gene) is bound by Isometheptene (Compound)
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isomethepten... |
DB00046 | DB06343 | 1,179 | 1,379 | [
"DDInter940",
"DDInter1766"
] | Insulin lispro | Teprotumumab | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Moderate | 1 | [
[
[
1179,
24,
1379
]
],
[
[
1179,
24,
959
],
[
959,
24,
1379
]
],
[
[
1179,
24,
1450
],
[
1450,
63,
1379
]
],
[
[
1179,
24,
959
],
[
959,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin... |
DB01591 | DB06176 | 667 | 1,342 | [
"DDInter1696",
"DDInter1616"
] | Solifenacin | Romidepsin | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
667,
24,
1342
]
],
[
[
667,
62,
112
],
[
112,
23,
1342
]
],
[
[
667,
63,
485
],
[
485,
24,
1342
]
],
[
[
667,
24,
1616
],
[
1616,
... | [
[
[
"Solifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Solifenacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and P... |
DB00877 | DB00959 | 629 | 1,486 | [
"DDInter1678",
"DDInter1191"
] | Sirolimus | Methylprednisolone | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
629,
24,
1486
]
],
[
[
629,
63,
175
],
[
175,
40,
1486
]
],
[
[
629,
63,
167
],
[
167,
1,
1486
]
],
[
[
629,
24,
1220
],
[
1220,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB00705 | DB04845 | 441 | 309 | [
"DDInter496",
"DDInter1001"
] | Delavirdine | Ixabepilone | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
441,
24,
309
]
],
[
[
441,
6,
8374
],
[
8374,
45,
309
]
],
[
[
441,
21,
28987
],
[
28987,
60,
309
]
],
[
[
441,
63,
1419
],
[
1419,
... | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Delavirdine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Delavirdine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Delavirdine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Ixabepilone (Compound)
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatini... |
DB00559 | DB09330 | 152 | 985 | [
"DDInter223",
"DDInter1352"
] | Bosentan | Osimertinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
152,
24,
985
]
],
[
[
152,
62,
168
],
[
168,
23,
985
]
],
[
[
152,
24,
112
],
[
112,
23,
985
]
],
[
[
152,
24,
1478
],
[
1478,
2... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"... | Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidaz... |
DB00214 | DB09135 | 1,028 | 1,211 | [
"DDInter1836",
"DDInter967"
] | Torasemide | Ioxilan | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
1028,
24,
1211
]
],
[
[
1028,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
1028,
24,
1287
],
[
1287,
25,
1211
]
],
[
[
1028,
25,
1448
],
[
14... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amp... |
DB00427 | DB06700 | 1,233 | 643 | [
"DDInter1879",
"DDInter511"
] | Triprolidine | Desvenlafaxine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1233,
24,
643
]
],
[
[
1233,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1233,
24,
1311
],
[
1311,
24,
643
]
],
[
[
1233,
63,
1594
],
[
1594,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate inte... |
DB01222 | DB08880 | 617 | 1,510 | [
"DDInter246",
"DDInter1771"
] | Budesonide | Teriflunomide | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
617,
25,
1510
]
],
[
[
617,
62,
1461
],
[
1461,
23,
1510
]
],
[
[
617,
23,
1193
],
[
1193,
62,
1510
]
],
[
[
617,
24,
221
],
[
221,
... | [
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Budesonide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Budesonide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gl... |
DB00252 | DB09036 | 362 | 812 | [
"DDInter1460",
"DDInter1668"
] | Phenytoin | Siltuximab | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
362,
24,
812
]
],
[
[
362,
25,
792
],
[
792,
24,
812
]
],
[
[
362,
24,
1031
],
[
1031,
24,
812
]
],
[
[
362,
23,
608
],
[
608,
2... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban... | Phenytoin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may ca... |
DB00679 | DB08938 | 684 | 1,384 | [
"DDInter1796",
"DDInter1112"
] | Thioridazine | Magaldrate | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
684,
23,
1384
]
],
[
[
684,
24,
167
],
[
167,
23,
1384
]
],
[
[
684,
40,
1178
],
[
1178,
23,
1384
]
],
[
[
684,
64,
752
],
[
752,
... | [
[
[
"Thioridazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Thioridazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a minor inter... |
DB00700 | DB06292 | 312 | 549 | [
"DDInter656",
"DDInter474"
] | Eplerenone | Dapagliflozin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
312,
24,
549
]
],
[
[
312,
24,
1344
],
[
1344,
40,
549
]
],
[
[
312,
6,
8374
],
[
8374,
45,
549
]
],
[
[
312,
21,
28882
],
[
28882,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Eplerenone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound)
Eplerenone (Compound) causes Body temperature increase... |
DB08881 | DB12332 | 868 | 1,619 | [
"DDInter1925",
"DDInter1626"
] | Vemurafenib | Rucaparib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
868,
25,
1619
]
],
[
[
868,
63,
307
],
[
307,
23,
1619
]
],
[
[
868,
23,
271
],
[
271,
23,
1619
]
],
[
[
868,
62,
112
],
[
112,
... | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil"... | Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron ... |
DB00176 | DB01168 | 529 | 1,053 | [
"DDInter770",
"DDInter1526"
] | Fluvoxamine | Procarbazine | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
529,
25,
1053
]
],
[
[
529,
24,
848
],
[
848,
40,
1053
]
],
[
[
529,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
529,
24,
126
],
[
126,
... | [
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprof... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Fluvoxamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Fluvoxamine may cause a moderate interacti... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.